内皮细胞JAK2V617F突变导致骨髓增殖性肿瘤小鼠模型血栓、血管病变和心肌病
该研究利用在特定细胞谱系表达JAK2V617F的小鼠模型,发现当突变同时存在于血液细胞和血管内皮细胞时,小鼠出现MPN、自发性年龄相关扩张型心肌病、猝死风险增加及血栓和血管病变表型;而仅血液细胞突变的小鼠无心脏功能障碍。突变内皮细胞呈现促黏附、促炎和血管病变表型,对血流剪切力反应异常。提示靶向MPN血管系统是潜在治疗策略。
要点
- 内皮细胞JAK2V617F突变是MPN心血管并发症的关键因素
- 仅血液细胞突变不足以引起心脏功能障碍
- 靶向MPN血管系统可能成为新的治疗策略
核心结论
- JAK2V617F突变可改变血管内皮功能,促进MPN患者心血管并发症。
- 靶向MPN血管系统是MPN患者有前景的新治疗策略。
研究设计与样本
- 研究采用在特定细胞谱系表达JAK2V617F突变的MPN小鼠模型。
- 比较了血液细胞和血管内皮细胞同时表达突变与仅血液细胞表达突变的小鼠。
主要发现
- 血液细胞和内皮细胞均表达JAK2V617F的小鼠出现MPN、自发性年龄相关扩张型心肌病、猝死风险增加及血栓和血管病变表型。
- 仅血液细胞表达JAK2V617F的小鼠白细胞和血小板计数显著高于对照,但无心脏功能障碍。
- JAK2V617F突变促进内皮细胞促黏附、促炎和血管病变表型,突变内皮细胞对血流剪切力反应与野生型不同。
临床怎么用
- 在MPN患者中应关注心血管并发症风险,尤其存在内皮细胞JAK2V617F突变时。
- 靶向MPN血管系统可能成为改善MPN患者心血管预后的新策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Cardiovascular complications are the leading cause of morbidity and mortality in patients with myeloproliferative neoplasms (MPNs). The acquired kinase mutation JAK2V617F plays a central role in these disorders. Mechanisms responsible for cardiovascular dysfunction in MPNs are not fully understood, limiting the effectiveness of current treatment. Vascular endothelial cells (ECs) carrying the JAK2V617F mutation can be detected in patients with MPNs. The goal of this study was to test the hypothesis that the JAK2V617F mutation alters endothelial function to promote cardiovascular complications in patients with MPNs. APPROACH AND RESULTS: We employed murine models of MPN in which the JAK2V617F mutation is expressed in specific cell lineages. When JAK2V617F is expressed in both blood cells and vascular ECs, the mice developed MPN and spontaneous, age-related dilated cardiomyopathy with an increased risk of sudden death as well as a prothrombotic and vasculopathy phenotype on histology evaluation. In contrast, despite having significantly higher leukocyte and platelet counts than controls, mice with JAK2V617F-mutant blood cells alone did not demonstrate any cardiac dysfunction, suggesting that JAK2V617F-mutant ECs are required for this cardiovascular disease phenotype. Furthermore, we demonstrated that the JAK2V617F mutation promotes a pro-adhesive, pro-inflammatory, and vasculopathy EC phenotype, and mutant ECs respond to flow shear differently than wild-type ECs. CONCLUSIONS: These findings suggest that the JAK2V617F mutation can alter vascular endothelial function to promote cardiovascular complications in MPNs. Therefore, targeting the MPN vasculature represents a promising new therapeutic strategy for patients with MPNs.
引用
- Castiglione M, Jiang YP, Mazzeo C, et al. Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm. J Thromb Haemost. 2020. PMID: 32920974. doi:10.1111/jth.15095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。